Glycopyrrolate - Sunovion Respiratory Development/PARI Pharma

Drug Profile

Glycopyrrolate - Sunovion Respiratory Development/PARI Pharma

Alternative Names: EP-101; Glycopyrrolate bromide; SUN-101; SUN-101/eFlow®

Latest Information Update: 10 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Elevation Pharmaceuticals
  • Developer PARI Pharma GmbH; Sunovion Respiratory Development
  • Class Antiasthmatics; Antispasmodics; Pyrrolidines; Quaternary ammonium compounds; Skin disorder therapies; Small molecules
  • Mechanism of Action Muscarinic receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Preregistration Chronic obstructive pulmonary disease
  • Phase II Asthma

Most Recent Events

  • 04 Jul 2017 Planned Prescription Drug User Fee Act (PDUFA) date for Chronic obstructive pulmonary disease in USA (Inhalation) is 2017-12-15
  • 30 Jun 2017 The US FDA accepts the re-submitted NDA for Glycopyrrolate (SUN-101/eFlow®) for Chronic obstructive pulmonary disease for review
  • 26 May 2017 Sunovion Pharmaceuticals receives complete response letter from the FDA for Glycopyrrolate (eFlow®) in Chronic obstructive pulmonary disease
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top